Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 214 clinical trials
None
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

characteristics of enrolled patients: Patients with initially unresectable biliary tract cancer; Interventions: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab; Sample size: 10 patients;

  • 0 views
  • 16 Aug, 2021
  • 1 location
None
  • 19 views
  • 01 Apr, 2021
  • 17 locations
None
Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

biliary tract cancer patients and have shown efficacy in small basket trials. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of mFOLFOX for gemcitabine

  • 0 views
  • 03 Feb, 2021
None
A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Biliary Tract Cancer

tract cancer patients who have progressed during or relapsed after at least one prior stand therapy.

  • 0 views
  • 22 Aug, 2021
  • 1 location
None
Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers

To verify the role of nab-paclitaxel in second or later-line treatment in advanced biliary tract cancers, the investigators designed a prospective, exploratory, single arm,single center phase II

  • 0 views
  • 23 Jan, 2021
  • 1 location
None
Clinical Validation of an Immunocytochemistry Method Using MARS1

usefulness of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using biliary cancer-related protein expressed only in bile duct cancer

  • 0 views
  • 22 Aug, 2021
  • 5 locations
None
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma

The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of

  • 0 views
  • 26 Aug, 2021
  • 2 locations
None
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy

IMMUNO-BIL is a non-comparative randomized 1:1 phase II study. This study will assess the efficacy and safety of the combination of durvalumab plus tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy. On the 25th June 2019, the maximum DLT event number was …

  • 2 views
  • 05 Feb, 2021
  • 42 locations
None
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are:

gemcitabine
platelet count
measurable disease
aptt
biliary tract cancer
  • 73 views
  • 24 Sep, 2021
  • 131 locations
None
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).

  • 0 views
  • 22 Aug, 2021
  • 59 locations